Siren Biotechnology's SVP of vector development, Nathalie Clément, Ph.D., explains the challenge of purifying AAV capsids and the ways developers are optimizing vector recovery.
- Implementing And Optimizing Your eQMS
- Novel Approach To Cancer Explores Severing Its Genetic Supply Line
- Choosing Analytical Technologies At The Right Stage Of Development
- Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs
- Unlocking The Future Of Cell And Gene Therapies
- Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics
- What Goes Into Restarting A Shelved Orphan Drug Candidate?
- A Much-Improved Approach For Understanding And Managing Safety Risks
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Unlocking The Full Potential Of Antibody-Drug Conjugates (ADCs)
ADCs are evolving rapidly. Gain insight into how success now hinges on managing complexity, delivery, and scalability to turn promising designs into viable therapeutic products.
-
Cell Culture Media Filtration: Evaluating Cell Culture Performance
Cell culture performance remained consistent across PES and PVDF filters, even under worst-case filtration conditions. Discover a practical framework for evaluating membrane impact on CHO cell growth.
-
Redefining Accessibility For Pediatric Patients
Explore how meeting patients where they are can redefine what successful pediatric trial delivery looks like.
-
Media Exchange In iPSC Cell Expansion And Differentiation: A Comparative Study
Low-shear, closed-system media exchange in iPSC differentiation is vital for scalability. This study compares automated centrifugation to gravity sedimentation, showing equivalent or superior differentiation outcomes.
-
Advancing An Integrated Biopharma Workflow Strategy
Global research teams were generating critical data in disconnected systems, hindering collaboration. Explore how unified workflows and a shared data backbone strengthen efficiency.
-
An Overview Of 2026 Life Sciences Industry Trends
Explore the paradigm shift reshaping life sciences. Learn how connecting data streams across the product lifecycle drives predictive compliance and operational excellence.
-
Guiding GLP-1 Participants Through The Challenge Of Retention
Learn how remote lifestyle coaching can combat high dropout rates in metabolic research by offering the support participants need to maintain adherence and ensure data integrity.
-
Faster, Cheaper Cell Therapy with At‑Line QC
Automated at‑line immunophenotyping QC streamlines cell therapy manufacturing, cutting turnaround time and cost while aligning with conventional methods and enabling scalable, reliable workflows.
-
A Novel Approach To Improving AAV Titers
As demand for AAV-based therapies rises, optimizing production processes is essential. By utilizing existing technologies, tailored platforms, and optimized formulations, titers and productivity can be enhanced.
-
Intuitive Bioprocess Scale-Up From Bench Scale To Pilot Scale
This study explores scaling a high-demand fed-batch process from bench to pilot scale, highlighting control parameter differences at 50L and 500L while maintaining consistent growth and product titers.
NEWSLETTER ARCHIVE
- 08.26.26 -- Optimizing Cold Chain & Cryo Logistics
- 08.26.26 -- Clinical Success Of Combination Cell Therapy Hinges On Manufacturability
- 08.25.26 -- OPCU: Advancing Large Molecule Programs Through Smarter Fill-Finish Planning
- 08.25.26 -- Why Vector Yield Remains The Biggest Bottleneck In Vivo Gene Therapy
- 08.25.26 -- Reimagine Solid Tumor Immunotherapy With SRC-3-Edited Tregs
- In Vivo CAR T Needs More Than Better Cell Engineering
- Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs
- Building Antigen-Specific Immune Tolerance For Autoimmune Disease
- Solving Vector Yield Challenges Starts Long Before Manufacturing
- Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections